While both peptides share similar geroprotective properties, Epitalon appears to differ in intensity and spectrum of action, possibly due to its structure or formulation [8, 9]
The pivotal SURMOUNT-1 trial showed mean weight reductions of approximately 15.0% with the 5 mg dose, 19.5% with the 10 mg dose, and 20.9% with the 15 mg dose at 72 weeks, compared to 3.1% with placebo
Import alerts allow for Detention Without Physical Examination (DWPE), which means FDA may detain the shipment without performing a physical analysis
By stimulating the release of GH, the peptide increases hypertrophy, i.e
Many compounded formulations contain semaglutide sodium or semaglutide acetate, chemical salt forms that differ from the base semaglutide used in FDA-approved medications such as Wegovy and Ozempic